As part of our NCI designation, the Chao Family Comprehensive Cancer Center's (CFCCC) Clinical Trials Protocol Review &Monitoring Committee (CTPRMC) serves as the primary Protocol Review and Monitoring System (PRMS). The CTPRMC reviews trials for scientific merit, adequacy of study design, and biostatistical concerns. The Committee also monitors trial accrual on an ongoing basis. The CTPRMC membership reflects the expertise required for the scientific review of trials and consists of CFCCC members and other faculty and staff from diverse fields necessary for complete review of investigator-initiated and pharmaceutical company sponsored trials. Currently, all studies involving cancer patients, including investigator-initiated protocols and industry sponsored trials, must undergo review by the CTPRMC prior to submission to, and review by, the Institutional Review Board (IRB). Studies that do not involve an intervention, such as observational, registry, specimen repository, and retrospective chart reviews studies, may qualify for CTPRMC exemption, as determined by the Director of the Clinical Research Office. In addition, cooperative group trials are exempt from initial review by the CTPRMC if they have received prior peer review by both the cooperative groups and the Clinical Trial Evaluation Program (CTEP). However, monitoring accrual for these trials remains a CTPRMC obligation. Prioritization of these trials is determined by the disease-specific groups at the CFCCC, supervised by the Associate Director for Clinical Research of the CFCCC. The CTPRMC meets twice monthly (alternating full Committee and sub-Committee), to review the essential protocol elements, including clear rationale, appropriate and efficient study design, biostatistical input, attainable accrual, and feasibility for completion within a reasonable time frame.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
United States
Zip Code
Wang, Yajun; Ngor, Arlene K; Nikoomanzar, Ali et al. (2018) Evolution of a General RNA-Cleaving FANA Enzyme. Nat Commun 9:5067
Qiu, Xiaolong; Lombardo, Jeremy A; Westerhof, Trisha M et al. (2018) Microfluidic filter device with nylon mesh membranes efficiently dissociates cell aggregates and digested tissue into single cells. Lab Chip 18:2776-2786
Patterson, Kurt; Yu, James; Landberg, Jenny et al. (2018) Functional genomics for the oleaginous yeast Yarrowia lipolytica. Metab Eng 48:184-196
Lee, J Scott; Roberts, Andrew; Juarez, Dennis et al. (2018) Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med 10:
Sierra, Robert A; Hoverter, Nathan P; Ramirez, Ricardo N et al. (2018) TCF7L1 suppresses primitive streak gene expression to support human embryonic stem cell pluripotency. Development 145:
Maciejewski, Sonia; Ullmer, Wendy; Semler, Bert L (2018) VPg unlinkase/TDP2 in cardiovirus infected cells: Re-localization and proteolytic cleavage. Virology 516:139-146
Konstorum, Anna; Lowengrub, John S (2018) Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model. J Theor Biol 439:86-99
Yan, Huaming; Konstorum, Anna; Lowengrub, John S (2018) Three-Dimensional Spatiotemporal Modeling of Colon Cancer Organoids Reveals that Multimodal Control of Stem Cell Self-Renewal is a Critical Determinant of Size and Shape in Early Stages of Tumor Growth. Bull Math Biol 80:1404-1433
Flather, Dylan; Nguyen, Joseph H C; Semler, Bert L et al. (2018) Exploitation of nuclear functions by human rhinovirus, a cytoplasmic RNA virus. PLoS Pathog 14:e1007277
Wang, Xiaolin; Zhao, Da; Phan, Duc T T et al. (2018) A hydrostatic pressure-driven passive micropump enhanced with siphon-based autofill function. Lab Chip 18:2167-2177

Showing the most recent 10 out of 1106 publications